BR112015017432A2 - métodos para o tratamento de indicações cardiovasculares - Google Patents

métodos para o tratamento de indicações cardiovasculares

Info

Publication number
BR112015017432A2
BR112015017432A2 BR112015017432A BR112015017432A BR112015017432A2 BR 112015017432 A2 BR112015017432 A2 BR 112015017432A2 BR 112015017432 A BR112015017432 A BR 112015017432A BR 112015017432 A BR112015017432 A BR 112015017432A BR 112015017432 A2 BR112015017432 A2 BR 112015017432A2
Authority
BR
Brazil
Prior art keywords
methods
treating cardiovascular
cardiovascular indications
treating
indications
Prior art date
Application number
BR112015017432A
Other languages
English (en)
Inventor
Holzmeister Johannes
Original Assignee
Cardiorentis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ltd filed Critical Cardiorentis Ltd
Publication of BR112015017432A2 publication Critical patent/BR112015017432A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)

Abstract

resumo patente de invenção: "métodos para o tratamento de indicações cardiovasculares". a presente invenção refere-se a um método de tratamento de uma indicação cardiovascular, que compreende a administração de um peptídeo natriurético a um paciente que possui a necessidade do mesmo dentro de 24 horas após a avaliação clínica do paciente.
BR112015017432A 2013-01-25 2014-01-24 métodos para o tratamento de indicações cardiovasculares BR112015017432A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756692P 2013-01-25 2013-01-25
PCT/IB2014/000253 WO2014115033A2 (en) 2013-01-25 2014-01-24 Methods of treating cardiovascular indications

Publications (1)

Publication Number Publication Date
BR112015017432A2 true BR112015017432A2 (pt) 2017-07-11

Family

ID=50382492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017432A BR112015017432A2 (pt) 2013-01-25 2014-01-24 métodos para o tratamento de indicações cardiovasculares

Country Status (19)

Country Link
US (2) US20140213519A1 (pt)
EP (1) EP2948165A2 (pt)
JP (1) JP2016505065A (pt)
KR (1) KR20150108903A (pt)
CN (1) CN105025918A (pt)
AP (1) AP2015008624A0 (pt)
AU (1) AU2014208851B2 (pt)
BR (1) BR112015017432A2 (pt)
CA (1) CA2898571A1 (pt)
DO (1) DOP2015000175A (pt)
EA (1) EA201500765A1 (pt)
IL (1) IL239909A0 (pt)
MX (1) MX2015009606A (pt)
NZ (1) NZ710246A (pt)
PH (1) PH12015501559A1 (pt)
SG (1) SG11201505492XA (pt)
TN (1) TN2015000315A1 (pt)
TW (1) TW201442722A (pt)
WO (1) WO2014115033A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184248A1 (en) * 2014-05-30 2015-12-03 Concert Pharmaceuticals, Inc. Methods of treating fibrotic diseases
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN110278941B (zh) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
JPH10500969A (ja) 1994-06-02 1998-01-27 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
NZ525389A (en) * 2000-10-04 2009-04-30 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
PL1865976T3 (pl) * 2005-04-07 2012-11-30 Cardiorentis Ag Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
ES2575397T3 (es) * 2007-09-11 2016-06-28 Cardiopep Pharma Gmbh Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
MX2010012502A (es) * 2008-05-16 2011-04-11 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
US8642550B2 (en) * 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
JP2010116325A (ja) * 2008-11-11 2010-05-27 Institute For Protein Science Co Ltd Ｓｉｒｓ患者を救命するためのペプチド組成物
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
RU2557290C2 (ru) * 2009-09-25 2015-07-20 Шайр Орфан Терапис ГмбХ Новые агонисты npr-b
WO2011113825A1 (en) * 2010-03-15 2011-09-22 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
AU2011291586A1 (en) * 2010-08-20 2013-03-07 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
TN2015000315A1 (en) 2017-01-03
US20140213520A1 (en) 2014-07-31
CA2898571A1 (en) 2014-07-31
DOP2015000175A (es) 2015-11-15
EP2948165A2 (en) 2015-12-02
JP2016505065A (ja) 2016-02-18
SG11201505492XA (en) 2015-08-28
EA201500765A1 (ru) 2015-12-30
KR20150108903A (ko) 2015-09-30
AP2015008624A0 (en) 2015-07-31
CN105025918A (zh) 2015-11-04
US20140213519A1 (en) 2014-07-31
AU2014208851A1 (en) 2015-08-06
MX2015009606A (es) 2016-04-26
WO2014115033A2 (en) 2014-07-31
AU2014208851B2 (en) 2016-12-22
NZ710246A (en) 2016-11-25
TW201442722A (zh) 2014-11-16
WO2014115033A3 (en) 2015-02-26
IL239909A0 (en) 2015-08-31
PH12015501559A1 (en) 2015-09-21

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
BR112015022197A2 (pt) tratamento de cataplexia
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
BR112014013780A2 (pt) transportador de seringa
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
BR112015006731A2 (pt) combinações e usos das mesmas
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015021681A2 (pt) proteínas de ligação para pcsk9
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112015024860A2 (pt) vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares
BR112013033051A2 (pt) roda dentada com endentação inclinada e segmento para uma roda dentada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]